|Podcasts|August 8, 2019
Episode 37: Differentiating Yourself in Crowded Therapeutic Areas
Author(s)Lisa Henderson, Christen Harm
Pharm Exec editors sit down with Mark Velleca, CEO of G1 Therapeutics. In this episode, Mark talks about how he differentiates himself in the oncology field, why he considers G1 Therapeutics an "old school company," and about the North Carolina biotech landscape.
Advertisement
Pharm Exec editors sit down with Mark Velleca, CEO of G1 Therapeutics. In this episode, Mark talks about how he differentiates himself in the oncology field, why he considers G1 Therapeutics an "old school company," and about the North Carolina biotech landscape.
You can listen and/or download the episode on SoundCloud, or directly through iTunes, GooglePlay, Stitcher, and Overcast.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
How Exposed is The U.S. Pharmaceutical Supply Chain to China’s Updated Export Control Regulations?
2
Staying Ahead of Viral Evolution: Q&A with Robert Allen, Ph.D
3
Bristol Myers Squibb Expands Collaboration with Nvidia to Build AI Factory
4
Pharmaceutical Executive Daily: Bristol Myers Squibb Expands Partnership with Nvidia
5